MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ctrv.2026.103121

Медицинская библиотека · Cancer treatment reviews · 2026

Hematological immune-related adverse events associated with checkpoint inhibitors.

Janson Mélanie, Cherifi François, Bardet Hippolyte, Damaj Gandhi

СтатьяОбзорКлинический случайПеревод в очереди

Аннотация

BACKGROUND

The use of immune checkpoint inhibitors (ICIs) has expanded substantially across tumor types, establishing them as a cornerstone of modern oncology. However, the frequency and severity of immune-related adverse events (irAEs) remain underestimated, particularly hematologic toxicities, which can be life-threatening and require distinct management approaches compared to cytotoxic or targeted therapies.

METHODS

We performed literature reviews using PubMed to identify and analyze reported cases of the most frequent hematologic irAEs; autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), and pure red cell aplasia (PRCA), in patients with solid tumors. In parallel, we report three illustrative cases from our institution to highlight diagnostic pitfalls and management strategies.

RESULTS

The median onset of hematologic irAEs occurs after approximately 3 cycles of ICI therapy for AIHA and ITP, and after 4 cycles for PRCA. Most patients achieved remission with corticosteroid therapy; however, 10-15% were steroid-refractory or relapsed, requiring second-line immunosuppressive agents. Rechallenge with ICIs remains controversial due to a recurrence rate of irAE, although it may be feasible and clinically beneficial in carefully selected patients.

CONCLUSION

As the use of ICIs continues to rise, prompt recognition and management of hematologic irAEs are critical to minimize morbidity and to avoid premature discontinuation of immunotherapy. Increased clinician awareness and standardized diagnostic algorithms are essential to preserve both safety and efficacy.

Для цитирования: Janson Mélanie, Cherifi François, Bardet Hippolyte, Damaj Gandhi. Hematological immune-related adverse events associated with checkpoint inhibitors.. Cancer treatment reviews. 2026. DOI: 10.1016/j.ctrv.2026.103121.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.